TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
AKTS

Aktis Oncology, Inc.

Healthcare · Biotechnology

22.90$ +0.7% vs. previous close Closing price · As of: Sep 17, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement AKTS
Line item 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
11.3% 648.9% 84.4% 70.2% 134.9% 127.0% 111.5% 1,887.9%
88.7% -548.9% 15.6% 29.8% -34.9% -27.0% -11.5% 100.0% 100.0%
690.1% 26,089.2% 1,098.4% 1,333.7% 1,146.5% 232.6% 95.6% 2,754.1% 1,038.2%
1,151.8% 35,482.7% 728.9% 603.0% 608.4% 134.9% 28.3% 760.4% 193.9%
1,742.0% 58,804.1% 1,827.3% 1,936.7% 1,755.0% 367.5% 128.3% 3,600.3% 1,249.5%
-1,842.0% -58,704.1% -1,844.4% -1,906.9% -1,789.8% -394.5% -128.3% -3,500.3% -1,149.5%
27.3% 200.0% 255.5% 0.5% 8.6% 178.7%
-2,121.4% -53,691.6% -1,799.8% -2,026.9% -2,019.0% -397.6% -105.6% -2,957.6% -980.9%
759.6% -10,013.7% 16.3% 113.0% -11.9% -9.0% 0.4%
-2,121.4% -53,691.6% -1,799.8% -2,139.9% -2,283.1% -385.6% -105.6% -2,957.6% -980.9%
-1,518.6% -62,329.0% -1,707.1% -1,737.4% -1,617.8% -344.1% -101.2% -2,851.7% -945.1%

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?